Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1

Toxicologic Pathology

Volumn 27, Issue 1, 1999, Pages 95-100

  Henry, Scott P ^a   Templin, Michael V ^a   Gillett, Nancy ^b   Rojko, Jennifer ^b   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

Antisense; Intercel lular adhesion molecule 1 (ICAM 1); Oligonucleotide; Pharmacokinetics; Phosphorothioate; Toxicity

Indexed keywords

ALICAFORSEN; INTERCELLULAR ADHESION MOLECULE 1; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG HALF LIFE; DRUG SAFETY; HISTOPATHOLOGY; IMMUNOTOXICITY; INTRAVENOUS DRUG ADMINISTRATION; LIVER TOXICITY; LYMPHOID HYPERPLASIA; MONKEY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; TISSUE DISTRIBUTION;

ANIMALIA; MURINAE; RODENTIA;

EID: 0033045917     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1177/019262339902700117     Document Type: Conference Paper

References (35)

1. Agrawal S, Temsamani J, Galbraith W, and Tang J (1995). Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28: 7-16.
2. Agrawal S, Temsamani J, and Tang JY (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc. Natl. Acad. Sci. USA 88: 7595-7599.
3. Bennett CF (1993). Antisense oligonucleotides in inflammation research. In: Antisense Research and Applications, ST Crooke and B Lebleu (eds). CRC Press, Boca Raton, Florida, pp. 547-562.
4. Bennett CF (1994). Inhibition of cell adhesion molecule expression with antisense oligonucleotides: Activity in-vitro and in-vivo. Clin. Chem. 40: 644-645.
5. Bennett CF (1998). Antisense oligonucleotides: Is the glass half full or half empty? Biochem. Pharmacol. 55: 9-19.
6. Bennett CF and Condon TP (1998). Use of antisense oligonucleotides to modify inflammatory processes. In: Antisense Research and Applications, ST Crooke (ed). Springer-Verlag, Berlin, pp. 371-393.
7. Bennett CF, Kornbrust D, Henry S, Stecker K, Howard R, Cooper S, Dutson S, Hall W, and Jacoby HI (1997). An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 280: 988-1000.
8. Branda RF, Moore AL, Mathews L, McCormack JJ, and Zon G (1993). Immune stimulation by an antisense oligomer complimentary to the rev gene of HIV-1. Biochem. Pharmacol. 45: 2037-2043.
9. Butler M, Stecker K, and Bennett CF (1997). Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab. Invest. 77: 379-388.
10. Butler M, Stecker K, and Bennett CF (1997). Histological localization of phosphorothioate oligodeoxynucleotides in normal rodent tissue. Nucleosides Nucleotides 16: 1761-1764.
11. Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, and Bennett CF (1991). Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266: 18162-18171.
12. 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats. J. Pharmacol. Exp. Ther. 269: 89-94.
13. Crooke ST and Bennett CF (1996). Progress in antisense oligonucleotide therapeutics. Annu. Rev. Pharmacol. Toxicol. 36: 107-129.
14. Geary RS, Leeds JM, Fitchett J, Burckin T, Troung L, Spainhour C, Creek M, and Levin AA (1997). Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression. Drug Metab. Dispos. 25: 1272-1281.
15. Geary RS, Leeds JM, Henry SP, Monteith DM, and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: I. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 383-394.
16. Geary RS, Leeds JM, Henry SP, Monteith D, Troung L, Fitchett J, Burckin T, and Levin AA. (1997). Pharmacokinetic properties of phosphorothioate oligonucleotides. In: Proceedings of the 12th International Roundiable - Nucleosides, Nucleotides, and their Biological Applications. September 15-19, 1997, in La Jolla, California.
17. Geary RS, Leeds JM, Shanahan W, Gover J, Pribble J, Truong L, Fitchett J, Burckin R, Nicklin P, Philips J, and Levin AA (1996). Sequence Independent Plasma and Tissue Pharmacokinetics for 3 Antisense Phosphorothioate Oligonucleotides: Mouse to Man. Plenum, Seattle, Washington.
18. Glover JM, Leeds JM, Mant TGK, Kisner DL, Zuckerman J, Levin AA, and Shanahan WR (1997). Phase I safety and pharmacokinetic profile of an ICAM-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther. 282: 1173-1180.
19. Henry SP, Bolte H, Auletta C, and Kornbrust DJ (1997). Evaluation of the toxicity of ISIS 2302, a phosphorothioate oligonucleotide, in a 4-week study in cynomolgus monkeys. Toxicology 120: 145-155.
20. Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, and Kornbrust DJ (1997). Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: Potential mechanism of action. J. Pharmacol. Exp. Ther. 281: 810-816.
21. Henry SP, Monteith D, and Levin AA (1997). Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicologic properties of phosphorothioate oligodeoxynucleotides. Anti-Cancer Drug Des. 12: 395-408.
22. Henry SP, Novotny W, Leeds J, Auletta C, and Kornbrust DJ (1997). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7: 503-510.
23. Henry SP, Taylor J, Midgley L, Levin AA, and Kornbrust DJ (1997). Evaluation of the toxicity profile of ISIS 2302, a phosphorothioate oligonucleotide in a 4-week study in CD-1 mice. Antisense Nucleic Acid Drug Dev. 7: 473-481.
24. Klinman DM, Kyung YAE, Beaucage SL, Conover J, and Krieg AM (1996). CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc. Natl. Acad. Sci. USA 93: 2879-2883.
25. Krieg AM, Matson S, and Fisher E (1996). Oligonucleotide modification determines the magnitude of B-cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev. 6: 133-139.
26. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, and Klinman DM (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549.
27. Kumasaka T, Quinlan WM, Doyle NA, Condon TP, Bennett CF, Sligh J, Beaudet AL, and Doerschuk CM (1995). The role of ICAM-1 in E. coli endotoxin-induced pneumonia evaluated using ICAM-1 mutant mice or ICAM-1 anti-sense oligonucleotides. Am. Rev. Respir. Dis. 151: A456.
28. Levin AA, Monteith DK, Leeds JM, Nicklin PL, Geary RS, Butler M, Templin MV, and Henry SP (1998). Toxicity of oligodeoxynucleotide therapeutic agents. In: Antisense Research and Applications, ST Crooke (ed). Springer-Verlag, Berlin, pp. 169-215.
29. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, Bennett CF, and Crooke ST (1997). Immune stimulation - A class effect of phosphorothioate oligodeoxynucleotides in rodents. Anti-Cancer Drug Des. 12: 421-432.
30. Pisetsky DS and Reich CF (1994). Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus. Life Sci. 54: 101-107.
31. Quinlan WM, Doyle NA, Kumasaka T, Wancewicz E, Bennett CF, and Doerschuk CM (1994). The effect of ICAM-1 anti-sense oligonucleotides on the expression of ICAM-1 mRNA induced by E. coli endotoxin. Am. Rev. Respir. Dis. 150: A325.
32. Stepkowski SM, Tu Y, Condon TP, and Bennett CF (1994). Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities. J. Immunol. 153: 5336-5346.
33. Stepkowski SM, Wang ME, Amante A, Kalinin D, Qu X, Blasdel T, Condon T, Kahan BD, and Bennett CF (1997). Antisense ICAM-1 oligonucleotides block allograft rejection in rats. Transplant. Proc. 29: 1285.
34. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, Rothlein RA, Mainolfi E, Tami JA, Bennett CF, Kisner DL, and Shanahan WR (1998). A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of steroid-dependent Crohn's disease. Gastroenerology 114: 1133-1142.
35. Zhao Q, Temsamani J, Zhou RZ, and Agrawal S (1997). Pattern and kinetics of cytokine production following administration of phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 7: 495-502.